Angelina Meier, DO
Family Medicine · Pittsburgh, PANPI 1316358500
Payments from drug & device makers
Across 376 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Daiichi Sankyo Inc.$795
- Pfizer$650
- Amgen$474
- Lilly USA, LLC$468
- Novo Nordisk$462
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,20598%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,233 |
| Daiichi Sankyo Inc. | 46 | $795 |
| Pfizer | 37 | $650 |
| Amgen | 34 | $474 |
| Lilly USA, LLC | 34 | $468 |
| Novo Nordisk | 32 | $462 |
| Abbott | 23 | $440 |
| Astellas Pharma US Inc | 19 | $330 |
| GSK | 19 | $291 |
| Teva Pharmaceuticals USA, Inc. | 10 | $143 |
| AstraZeneca | 10 | $141 |
| Exact Sciences | 6 | $111 |
| Johnson & Johnson | 6 | $88 |
| Nestle Healthcare Nutrition Inc. | 5 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $62 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Merck | 2 | $32 |
| Novartis | 2 | $31 |
| Bayer | 2 | $30 |
| UCB, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Argenx US, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$6,305 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $43,072 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $37,398 |
| EliquisApixaban | 30 | $24,924 |
| TrulicityDulaglutide | 14 | $23,748 |
| MyrbetriqMirabegron | 34 | $19,769 |
| JardianceEmpagliflozin | 11 | $16,792 |
| MounjaroTirzepatide | 13 | $13,352 |
| LinzessLinaclotide | 14 | $9,889 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,233 |
| Atorvastatin Calcium | 267 | $2,593 |
| SynthroidLevothyroxine Sodium | 29 | $2,401 |
| Ezetimibe | 55 | $1,586 |
| Duloxetine Hcl | 38 | $1,462 |
| Bupropion XlBupropion Hcl | 17 | $1,229 |
| Levothyroxine Sodium | 128 | $1,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $462 | $43,07239 claims |
| GSKTrelegy Ellipta | $291 | $37,39845 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $468 | $37,10027 claims |
| PfizerEliquis | $650 | $24,92430 claims |
| Astellas Pharma US IncMyrbetriq | $330 | $19,76934 claims |
| Boehringer IngelheimJardiance | $21 | $16,79211 claims |
| AbbVieLinzess, Synthroid | $1,233 | $12,29043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Pittsburgh
- Bryce PalchickPittsburgh$4.7M
- Shari RozenPittsburgh$2.9M
- Nathan BennettPittsburgh$1.6M
- James MorettiPittsburgh$1.5M
- Michael GatesPittsburgh$608K
- Daniel AustinPittsburgh$598K
- Norman KolbPittsburgh$81K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.